Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Planchard

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?A Mavrikios, M Bortolot, C Le Péchoux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted TherapiesM Aldea, S Lenahan, M-A Locquet, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?A Mavrikios, M Bortolot, C Le Péchoux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted TherapiesM Aldea, S Lenahan, M-A Locquet, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Pageof 6